starpharma | home
home
about starpharma
technology
product pipeline
news room
investor relations
 careers contact us
site search
News Room
 
 
 September 2010
Appendix 3B
2/09/2010
 August 2010
Orbis Increases its stake in Starpharma to 12.54%
27/08/2010
Annual Report and Full Year Financial Results
25/08/2010
VivaGel Condom Patent Grant Extends Coverage
18/08/2010
Employee Performance Rights Plan and Offers
17/08/2010
Starpharma Announces Phase 2 BV Study of VivaGel
16/08/2010
 July 2010
Appendix 4C - Quarterly Report
27/07/2010
SPL Partner SSL Announces Recommended Cash Offer
22/07/2010
Lapse of Unquoted Options
19/07/2010
Starpharma`s Bacterial Vaginosis Study gets FDA Clearance
15/07/2010
Starpharma Appoints Further VP Business Development
12/07/2010
Expiry of options - change of director`s interest notice
5/07/2010
Lapse of unquoted employee share options
5/07/2010
Change of Director`s Interest Notice
1/07/2010
 June 2010
SPL and Monash University collaboration receives ARC grant
29/06/2010
Appendix 3B
24/06/2010
Orbis acquires further 6.55m shares in Starpharma increasing its holding to 11.46%
23/06/2010
Orbis increases its stake in Starpharma to 8.71%
21/06/2010
Change of Director`s Interest Notice
15/06/2010
 May 2010
Starpharma CEO Joins Melbourne Business School Board of Directors
7/05/2010
 April 2010
Shareholder Update May 2010
29/04/2010
Appendix 4C - Quarterly Report
27/04/2010
 March 2010
Change of Director`s Interest Notice
31/03/2010
Appendix 3B
31/03/2010
Results of Meeting
30/03/2010
Successful completion of VivaGel study in sexually active women
12/03/2010
 February 2010
Appendix 3B
25/02/2010
Notice of Extraordinary General Meeting/Proxy Form
22/02/2010
Shareholder Update February 2010
11/02/2010
Appendix 3B
9/02/2010
Starpharma and Lilly Sign New Drug Delivery Collaboration
1/02/2010
 January 2010
Appendix 4C - quarterly
29/01/2010
Appendix 3B
28/01/2010
Appendix 3B
21/01/2010
Lapse of Unquoted Options
5/01/2010
 November 2009
Becoming a Substantial Holder - Orbis Australia
24/11/2009
Cleansing Statement
24/11/2009
Appendix 3B
24/11/2009
Starpharma announces $15.6 million capital raising
18/11/2009
Suspended at the request of company
16/11/2009
Results of Meeting
13/11/2009
AGM Chairman`s and CEO`s Presentations
12/11/2009
Starpharma signs agrochemicals deal
5/11/2009
 October 2009
New legislation results in withdrawal of CEO incentive schem
29/10/2009
Appendix 4C - Quaterly Report
23/10/2009
Notice of Annual General Meeting/Proxy Form
13/10/2009
 September 2009
2009 Annual Report (1.1 MB)
30/09/2009
US Patent Grant Extends VivaGel Coverage to 2024
22/09/2009
Release of Shares From Escrow
18/09/2009
Shareholder Update
17/09/2009